Novel Bioassay Developed to Determine Glucocorticoid Sensitivity
By LabMedica International staff writers Posted on 25 Jan 2017 |
Image: The Skatron Micro 96 semi-automatic cell harvester (Photo courtesy of Cox Scientific).
Glucocorticoids (GCs) remain the first line treatment for almost all non-infectious inflammatory diseases, ranging from acute asthma to rheumatoid arthritis. However, across all conditions, patients have a variable response to GCs with approximately 30% being non-responders.
There is a pressing clinical need for a predictive biomarker of GC responsiveness and the availability of such a tool would also enable patient stratification for the conduct of smart clinical trials in GC resistance. Lymphocyte GC sensitivity has been shown to be closely associated with clinical GC sensitivity in a number of inflammatory diseases.
Clinical scientists at the University of Bristol took peripheral blood samples from healthy subjects by standard venipuncture into EDTA collection tubes. Peripheral blood monocytes were isolated by density gradient centrifugation using Leucosep tubes and cell viability assessed by Trypan blue exclusion. Cells were counted manually by light microscopy using a hemocytometer.
Dexamethasone inhibition of lymphocyte proliferation assays (DILPA) were performed and plates were harvested onto glass fiber filter paper using a Skatron cell harvester. The scientists then optimized and validated a novel non-radioactive in vitro bioassay based on measuring cellular proliferation by incorporation of bromodeoxyuridine (BrdU), termed the BrdU incorporation in lymphocyte steroid sensitivity assay (BLISS). The novel BLISS assay to determine GC sensitivity had a suitably high area under receiver operating characteristic (AUROC, 0.82) and sensitivity in correctly identifying GC non-responders (83%) in reference to the existing gold standard lymphocyte GC sensitivity assessment method (DILPA). The sensitivity of BLISS in identifying GC non-responders is the most important measure of diagnostic accuracy; it must correctly identify those patients who do not respond to GCs so as to reliably reduce their unnecessary exposure to GCs and guide alternative management.
The authors concluded that they had validated a simple novel bioassay with a standardized laboratory protocol, which accurately measures GC sensitivity. This has broad translational implications and could be applied to many inflammatory diseases to guide clinical management of individual patients, ensuring that GC responsive patients are correctly treated with GCs while reducing unnecessary exposure to GCs and accelerating the appropriate escalation of treatment of GC resistant patients. The study was published on December 15, 2016, in the journal Biomarker Research.
There is a pressing clinical need for a predictive biomarker of GC responsiveness and the availability of such a tool would also enable patient stratification for the conduct of smart clinical trials in GC resistance. Lymphocyte GC sensitivity has been shown to be closely associated with clinical GC sensitivity in a number of inflammatory diseases.
Clinical scientists at the University of Bristol took peripheral blood samples from healthy subjects by standard venipuncture into EDTA collection tubes. Peripheral blood monocytes were isolated by density gradient centrifugation using Leucosep tubes and cell viability assessed by Trypan blue exclusion. Cells were counted manually by light microscopy using a hemocytometer.
Dexamethasone inhibition of lymphocyte proliferation assays (DILPA) were performed and plates were harvested onto glass fiber filter paper using a Skatron cell harvester. The scientists then optimized and validated a novel non-radioactive in vitro bioassay based on measuring cellular proliferation by incorporation of bromodeoxyuridine (BrdU), termed the BrdU incorporation in lymphocyte steroid sensitivity assay (BLISS). The novel BLISS assay to determine GC sensitivity had a suitably high area under receiver operating characteristic (AUROC, 0.82) and sensitivity in correctly identifying GC non-responders (83%) in reference to the existing gold standard lymphocyte GC sensitivity assessment method (DILPA). The sensitivity of BLISS in identifying GC non-responders is the most important measure of diagnostic accuracy; it must correctly identify those patients who do not respond to GCs so as to reliably reduce their unnecessary exposure to GCs and guide alternative management.
The authors concluded that they had validated a simple novel bioassay with a standardized laboratory protocol, which accurately measures GC sensitivity. This has broad translational implications and could be applied to many inflammatory diseases to guide clinical management of individual patients, ensuring that GC responsive patients are correctly treated with GCs while reducing unnecessary exposure to GCs and accelerating the appropriate escalation of treatment of GC resistant patients. The study was published on December 15, 2016, in the journal Biomarker Research.
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form